Tags
- 2030
- A
- Adult
- Agonist
- Analyst
- Anticipation
- Anti-obesity medication
- Appetite
- Approval
- Approved
- Being
- Belong
- Biologic
- Biopharmaceutical
- Blockbuster
- Bloomberg
- Bloomberg intelligence
- Body
- Category
- Challenge
- China
- Chinese
- Chinese people
- Compete
- Competition
- Containment
- Data
- Demonstration
- Develop
- Diabetes
- Diabetes mellitus type 2
- Differently
- Dose
- Drug
- Drugs
- Economy
- Economy of China
- Efficacy
- Eli Lilly
- End
- Estimate
- Estimates
- Experimental
- Experimental treatment
- Expiration
- Fat
- Generic
- Generic drug
- Glucagon-like peptide-1
- Glucagon-like peptide 1 receptor
- Goldman
- Goldman Sachs
- Government data
- Han Chinese
- Hormone
- Human body weight
- Ingredient
- Injection
- Intelligence
- Intelligence analysis
- In the Country
- Known
- Leslie Yang
- Liver
- Loss
- Market
- Meanwhile
- Medicine
- Michael Shah
- Mounjaro
- Much
- New
- Nordisk
- Novo
- Novo Nordisk
- Obesity
- Off-label use
- Originally
- Overweight
- Ozempic
- Participation
- Patent
- Patient
- Pharmaceutical drug
- Placebo
- Pound
- Product
- Racing
- Receptor
- Reduce
- Reduction
- Refueling
- Result
- Sachs
- Sale
- Sales
- Shedding
- Targeting
- Term of patent
- Tested
- The Decade
- The Drugs
- The end
- The way
- The world
- Treat
- Treating
- Trial
- Versions
- Wegovy
- Weight
- Weight loss
- Who
- Zepbound